Participation at the IASLC 2022 WCLC World Conference on Lung Cancer

TRACEPIGEN participant Milena Cavic attended the World Lung Cancer Congress (WCLC22) organized by the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria, August 5-9, 2022. WCLC22 is traditionally the world’s largest international gathering of clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. The congress covered a variety of topics related to lung cancer research, early detection, screening, clinical management, clinical trials, drug updates, and smoking cessation, among others.  


At the congress, Milena Cavic presented an abstract “Current status, challenges and perspectives of lung cancer screening in low- and middle-income countries”, during a poster viewing session on August 7, 2022. The abstract highlighted that current literature data on the status of lung cancer screening in low- and middle-income countries is scarce, often opinion-based or relates to one specific country/region/project. The main aim of this interim report was to outline the current obstacles and perspectives of lung cancer screening in LMIC and to propose guidance, recommendations, and future research strategies. The abstract merited special attention and was selected for a press release during a daily congress highlights session with a 10-minute presentation held on August 7, 2022. Dr Cavic also participated at WCLC22 as the co-chair of the IASLC Diagnostics Working Group of the IASLC Early Detection and Screening Committee, during a Committee corner session held on August 8, 2022, Committee meeting held on August 7, 2022 and Screening Symposium held on August 5, 2022. Dr Cavic was a moderator of a session “ES20: Management of Lung Cancer in the Era of COVID-19 II” held on August 8, 2022. All these activities were very useful for the dissemination of TRACEPIGEN project results and networking with potential new collaborators.  

Like this article?

Leave a comment

Latest posts

Martínez-Ruiz et. al. Nature 2023

Martínez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, Thol K, Jones TP, Veeriah S, Naceur-Lombardelli C, Toncheva A, Prymas P, Rowan A, Ward S, Cubitt L, Athanasopoulou F, Pich O, Karasaki T, Moore DA, Salgado R, Colliver E, Castignani C, Dietzen M, Huebner A, Al Bakir M, Tanić M, Watkins

Ostojic. et. al. Journal of molecular medicine. 2023

Ostojić, M., Jevrić, M., Mitrović-Ajtić, O., Živić, K., Tanić, M., Čavić, M., Srdić-Rajić, T., & Grahovac, J. (2023). Nischarin expression may have differing roles in male and female melanoma patients. Journal of molecular medicine (Berlin, Germany), 101(8), 1001–1014.

Popović Krneta et. al.  Journal of clinical medicine 2023

Popović Krneta, M., Šobić Šaranović, D., Mijatović Teodorović, L., Krajčinović, N., Avramović, N., Bojović, Ž., Bukumirić, Z., Marković, I., Rajšić, S., Djorović, B. B., Artiko, V., Karličić, M., & Tanić, M. (2023). Prediction of Cervical Lymph Node Metastasis in Clinically Node-Negative T1 and T2 Papillary Thyroid Carcinoma Using Supervised Machine Learning Approach. Journal of clinical medicine, 12(11),

Vukovic et. al. Translational Oncology 2023

Vukovic, M., Tanic, M., Damjanovic, A., Pavlovic, M., Stanojevic, A., Zivic, K., Karadzic, V., Jankovic, R., & Cavic, M. (2023). EGFR mutation testing from pleural effusions of non-small cell lung cancer patients at the institute for oncology and radiology of Serbia. Translational oncology, 37, 101772.

Tanić et al. Nature Biotechnology 2022

M Tanić, I. Moghul, S. Rodney, P. Dhami, H. Vaikkinen, J. Ambrose, J. Barrett, A. Feber, S. Beck. Performance comparison and in-silico harmonisation of commercial platforms for DNA methylome analysis by targeted bisulfite sequencing. Nature Biotechnology 2022.

Cavic et al. Oncology, 2022

Cavic, M., Kovacevic, T., Zaric, B., Stojiljkovic, D., Korda, N. J., Rancic, M., Jankovic, R., Radosavljevic, D., Stojanovic, G., & Spasic, J. (2022). Lung Cancer in Serbia. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17(7), 867–872.  

Scroll to Top